Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 5/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617732 | 0.89 | TYK2 (0.61) | PIK3CAPIK3CBPIK3CGFFAR1PDE10A | |
| SCHEMBL16583197 | 0.84 | PDE10A (0.66) | PIK3CAPIK3CBPIK3CGPDE10A | |
| SCHEMBL3560513 | 0.81 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CGFFAR1PDE10A | |
| SCHEMBL4134049 | 0.80 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CGFFAR1PDE10A | |
| SCHEMBL3554149 | 0.78 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL1310015 | 0.78 | PTGS2 (0.67) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL3552584 | 0.77 | PIK3CA (0.74) | PIK3CAPIK3CBPIK3CGFFAR1PDE10A | |
| SCHEMBL13406354 | 0.76 | TYK2 (0.58) | PIK3CAPIK3CBPIK3CGTYK2SYK | |
| SCHEMBL29997984 | 0.76 | L3MBTL1 (0.51) | PIK3CAPIK3CBPDE10AP2RY12LMNA | |
| SCHEMBL17827837 | 0.76 | L3MBTL1 (0.51) | PIK3CAPIK3CBPDE10AP2RY12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042810-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PIK3CA 1/4885PIK3CB 10/4885PIK3CG 15/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PIK3CA 137/4885PIK3CB 377/4885PIK3CG 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.